| __timestamp | Dynavax Technologies Corporation | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 1499100000 |
| Thursday, January 1, 2015 | 22180000 | 1923500000 |
| Friday, January 1, 2016 | 37257000 | 2351400000 |
| Sunday, January 1, 2017 | 27367000 | 2564000000 |
| Monday, January 1, 2018 | 64770000 | 2397300000 |
| Tuesday, January 1, 2019 | 74986000 | 2503400000 |
| Wednesday, January 1, 2020 | 79256000 | 3344600000 |
| Friday, January 1, 2021 | 100156000 | 4529200000 |
| Saturday, January 1, 2022 | 131408000 | 4179100000 |
| Sunday, January 1, 2023 | 152946000 | 4650100000 |
Data in motion
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Viatris Inc. and Dynavax Technologies Corporation have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023, a staggering 210% increase from 2014. In contrast, Dynavax Technologies Corporation, while significantly smaller, demonstrated a robust growth trajectory, with SG&A expenses rising by over 760% during the same period, reaching around $153 million in 2023.
This divergence highlights Viatris's expansive operational scale compared to Dynavax's agile growth strategy. As the industry continues to face challenges, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
Novartis AG and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Pfizer Inc. vs Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Insmed Incorporated vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Catalent, Inc. or Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Galapagos NV
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.